Insmed Unveils Late-Stage Data Across Respiratory Portfolio at ERS Congress 2026
Event summary
- Insmed to present five abstracts at ERS Congress 2026, including late-breaking Phase 3b ENCORE study results for ARIKAYCE in MAC lung disease.
- Data includes post hoc analysis of TPIP in pulmonary arterial hypertension and BRINSUPRI in non-cystic fibrosis bronchiectasis.
- Presentations cover psychosocial burden of bronchiectasis exacerbations and treatment patterns in Spain.
- ERS Congress 2026 takes place September 5–9, 2026, in Barcelona.
The big picture
Insmed's data presentations at ERS Congress 2026 underscore its focus on advancing treatments for serious respiratory diseases. The company is positioning itself as a leader in addressing unmet needs in non-cystic fibrosis bronchiectasis and pulmonary arterial hypertension, areas with limited existing therapies. The strategic emphasis on late-stage clinical data aims to strengthen its portfolio and potentially expand market opportunities.
What we're watching
- Clinical Efficacy
- Whether ARIKAYCE's Phase 3b ENCORE study results demonstrate sustained efficacy in reducing recurrence rates for MAC lung disease.
- Regulatory Pathway
- The pace at which Insmed can secure expanded approvals for ARIKAYCE and BRINSUPRI based on new data.
- Market Differentiation
- How TPIP's post hoc analysis data may position it as a differentiated therapy for pulmonary arterial hypertension.